China National Accord Medicines Corporation Ltd. (SZSE:000028) shareholders are probably feeling a little disappointed, since its shares fell 2.8% to CN¥27.88 in the week after its latest third-quarter results. It looks like the results were a bit of a negative overall. While revenues of CN¥19b were in line with analyst predictions, statutory earnings were less than expected, missing estimates by 8.1% to hit CN¥0.57 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

Taking into account the latest results, the consensus forecast from China National Accord Medicines' seven analysts is for revenues of CN¥82.1b in 2025. This reflects a decent 9.0% improvement in revenue compared to the last 12 months. Per-share earnings are expected to increase 9.5% to CN¥2.90. In the lead-up to this report, the analysts had been modelling revenues of CN¥82.4b and earnings per share (EPS) of CN¥2.96 in 2025. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

The analysts reconfirmed their price target of CN¥29.69, showing that the business is executing well and in line with expectations. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic China National Accord Medicines analyst has a price target of CN¥40.00 per share, while the most pessimistic values it at CN¥20.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The period to the end of 2025 brings more of the same, according to the analysts, with revenue forecast to display 7.1% growth on an annualised basis. That is in line with its 8.2% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 12% per year. So it's pretty clear that China National Accord Medicines is expected to grow slower than similar companies in the same industry.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that China National Accord Medicines' revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that in mind, we wouldn't be too quick to come to a conclusion on China National Accord Medicines. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for China National Accord Medicines going out to 2026, and you can see them free on our platform here..

Before you take the next step you should know about the 1 warning sign for China National Accord Medicines that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.